Enabling Early Assessment Of Drug Targets To Maximize Clinical And Commercial Success
Source: Syngene International Ltd.
![GettyImages-995087800-lab GettyImages-995087800-lab](https://vertassets.blob.core.windows.net/image/bab978c7/bab978c7-ebd8-470c-9340-a2a0c2d283cd/375_250-gettyimages_995087800_lab.jpg)
Target identification and validation is a major challenge in the pharmaceutical industry, with many promising treatments failing in the clinic for efficacy or target-related safety issues. The reason is usually that the underlying hypothesis turns out to be wrong, or there are unwanted consequences to modulating the target. Comprehensive diligence around a target before starting a discovery program can make the difference between success and failure.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.
Subscribe to Drug Discovery Online
X
Subscribe to Drug Discovery Online
This website uses cookies to ensure you get the best experience on our website. Learn more